2,177 results on '"Richards, A. Mark"'
Search Results
52. Computational Fluid Dynamics Modeling of Hemodynamic Parameters in the Human Diseased Aorta: A Systematic Review
53. Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: A phenomics approach
54. Serum Placental Growth Factor as a Marker of Cerebrovascular Disease Burden in Alzheimer’s Disease
55. Circulating erythroferrone has diagnostic utility for acute decompensated heart failure in patients presenting with acute or worsening dyspnea
56. Proteomic Correlates And Prognostic Significance Of Kidney Injury In Heart Failure With Preserved Ejection Fraction
57. Epitope-directed monoclonal antibody production using a mixed antigen cocktail facilitates antibody characterization and validation
58. Efficacy and safety of next-generation tick transcriptome-derived direct thrombin inhibitors
59. A deep learning pipeline for automatic analysis of multi-scan cardiovascular magnetic resonance
60. Lipid profiles and outcomes of patients with prior cancer and subsequent myocardial infarction or stroke
61. Author Correction: Epitope-directed monoclonal antibody production using a mixed antigen cocktail facilitates antibody characterization and validation
62. Variability of the Plasma Lipidome and Subclinical Coronary Atherosclerosis
63. MicroRNA-221 Is Cardioprotective and Anti-fibrotic in a Rat Model of Myocardial Infarction
64. Hemodynamic, Hormonal, and Renal Actions of Phosphodiesterase-9 Inhibition in Experimental Heart Failure
65. Analytical, biochemical and clearance considerations of soluble urokinase plasminogen activator receptor (suPAR) in healthy individuals
66. Sex Differences in 1-Year Rehospitalization for Heart Failure and Myocardial Infarction After Primary Percutaneous Coronary Intervention
67. Variability of the Plasma Lipidome and Subclinical Coronary Atherosclerosis
68. Combining Circulating MicroRNA and NT-proBNP to Detect and Categorize Heart Failure Subtypes
69. Convalescent Growth Differentiation Factor-15 and Long-Term Outcomes after an Acute Coronary Syndrome
70. Hybrid PET/CT and PET/MRI imaging of vulnerable coronary plaque and myocardial scar tissue in acute myocardial infarction
71. Longitudinal NT-proBNP: Associations With Echocardiographic Changes and Outcomes in Heart Failure.
72. Derivation and Validation of Thresholds Using Synthetic Data Methods for Single-Test Screening of Emergency Department Patients with Possible Acute Myocardial Infarction Using a Point-of-Care Troponin Assay.
73. Interrogating the Role of miR-125b and Its 3′isomiRs in Protection against Hypoxia
74. Combined Inhibition of Phosphodiesterases 5 and 9 in Experimental Heart Failure
75. Differential Associations of A-/B-Type Natriuretic Peptides With Cardiac Structure, Function, and Prognosis in Heart Failure
76. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study
77. MicroRNA-101a suppresses fibrotic programming in isolated cardiac fibroblasts and in vivo fibrosis following trans-aortic constriction
78. Plasma Ceramides as Prognostic Biomarkers and Their Arterial and Myocardial Tissue Correlates in Acute Myocardial Infarction
79. N-Terminal B-type Natriuretic Peptide in Heart Failure
80. Prioritizing Candidates of Post-Myocardial Infarction Heart Failure Using Plasma Proteomics and Single-Cell Transcriptomics
81. BNP as a biomarker in adult congenital heart disease: help or hype?
82. One-loop five-point amplitudes in string theory
83. Sacubitril/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded endpoint clinical trial protocol
84. MicroRNA-31 promotes adverse cardiac remodeling and dysfunction in ischemic heart disease
85. Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study
86. Risk Stratification Model for 30-Day Heart Failure Readmission in a Multiethnic South East Asian Community
87. Prevalence and Clinical Significance of Diabetes in Asian Versus White Patients With Heart Failure
88. Beta-blockers and renin-angiotensin system inhibitors in acute myocardial infarction managed with inhospital coronary revascularization
89. Association of Factor V Leiden With Subsequent Atherothrombotic Events: A GENIUS-CHD Study of Individual Participant Data
90. 2,2':6',2''-Terpyridine platinum(II) complexes and their interaction with DNA
91. Damage identification in engineering structures from changes in measured dynamic response
92. Associations of Blood Cardiovascular Biomarkers With Brain Free Water and Its Relationship to Cognitive Decline: A Diffusion-MRI Study
93. Plasma Markers to Risk Stratify for Heart Failure in Atrial Fibrillation
94. An integrated signature of extracellular matrix proteins and a diastolic function imaging parameter predicts post-MI long-term outcomes
95. Comparison of SPEED, S-Trap, and In-Solution-Based Sample Preparation Methods for Mass Spectrometry in Kidney Tissue and Plasma
96. Global longitudinal strain and plasma biomarkers for prognosis in heart failure complicated by diabetes
97. Novel Oxidative Stress Biomarkers with Risk Prognosis Values in Heart Failure
98. PROTEOMIC ASSOCIATIONS OF N-TERMINAL (NT)-PRO HORMONE BNP (NT-PROBNP) IN HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)
99. Diagnostic Accuracy of the Electrocardiogram for Heart Failure With Reduced or Preserved Ejection Fraction
100. EFFECT OF SPIRONOLACTONE ON THE PLASMA PROTEOME IN HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF): IMPACT OF BASELINE N-TERMINAL (NT)-PRO B-TYPE NATRIURETIC PEPTIDE (BNP) LEVELS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.